How is radioactive iodine (I‑131) therapy used for thyroid cancer and hyperthyroidism, including dosing, preparation, and safety precautions?

Radioactive Iodine (I-131) Therapy

Radioactive iodine therapy is a safe and effective targeted treatment for both hyperthyroidism and differentiated thyroid cancer, with dosing strategies ranging from fixed ablative doses (typically 10-15 mCi for hyperthyroidism, 30-100 mCi for thyroid cancer) to calculated approaches based on gland size and uptake, though high-dose ablation achieves superior cure rates exceeding 80%. 1, 2

For Hyperthyroidism (Graves' Disease)

Dosing Approaches

Two primary methods exist, though evidence shows no significant difference in achieving euthyroid status between them 1:

• Fixed ablative dose: 10-15 mCi (370-555 MBq) achieves success rates >80% 1

  • Above 15 mCi threshold, no additional benefit occurs even with large thyroid volumes 1
  • Simpler and equally effective as calculated methods

• Calculated dose: 75-200 microcuries/gram of thyroid tissue divided by 24-hour radioiodine uptake 3

  • More complex without proven superiority
  • May paradoxically result in higher doses than fixed approach 1

A practical formula based on gland size: I-131 dose (mCi) = 0.235 × gland weight (grams), with mean doses around 14.84 mCi 3

Pre-Treatment Preparation

Beta-blockers should be systematically administered in symptomatic hyperthyroidism due to 10-15% risk of transient thyrotoxicosis worsening post-treatment 1:

• Mandatory when antithyroid drugs contraindicated or poorly tolerated
• Prevents rare severe thyrotoxic crisis (0.3-0.5% of cases) 1

Antithyroid drug preparation is helpful especially in fragile patients (elderly, cardiovascular disease, severe symptoms) 1:

• Discontinue 3-7 days around radioiodine administration (no consensus on exact duration) 1
• Accelerates return to euthyroid status
• Improves tolerance during transient hyperthyroid phase

When antithyroid drugs contraindicated, lithium can be used to enhance treatment efficacy while allowing lower radioactivity 1

For Differentiated Thyroid Cancer

Three Clinical Objectives 2

1. Ablation: Destroy postoperative thyroid remnants (typical dose: 30 mCi/1110 MBq)
2. Adjuvant: Eliminate occult micrometastases (typical dose: 100 mCi/3.7 GBq)
3. Therapeutic: Treat known metastatic disease (doses: 150-200 mCi) 4

Preparation Protocol 2

• TSH stimulation: Either thyroid hormone withdrawal (endogenous) or recombinant human TSH injection (exogenous)
• Iodine-free diet prior to therapeutic dose 4
• Avoid iodine-containing drugs and contrast agents 2

Dosing Strategy

Activity stratified by risk classification 2:

• Low-dose: 20-30 mCi (740-1110 MBq), with 30 mCi more widely used
• High-dose: 100 mCi (3.7 GBq) or higher for adjuvant/therapeutic intent
• Metastatic disease: 150-200 mCi 4

Safety Precautions and Radiation Protection

Patient Isolation Requirements

Actual radiation exposure is substantially lower than regulatory models predict 5:

• Initial dose rates only 28-38% of Nuclear Regulatory Commission/American Thyroid Association model predictions 5
• Effective I-131 half-life in thyroid tissue: 47.6 hours (versus 175.2 hours in models) 5

Practical precaution times based on actual biokinetics 5, 6:

• 3.7 GBq (ablation) or 7.4 GBq (follow-up): 3 days sleeping apart from pregnant women/children to keep exposure <1 mSv
• No precautions required for non-cosleeping, non-pregnant adult family members 5

Hospital Safety Protocols 7

• Daily area surveys of hallways, stairwells, adjacent rooms documented
• Ensure doses to unrestricted areas ≤20 mcSv (2 mrem) per hour
• No items removed from isolation room until cleared by nuclear medicine/radiation safety personnel
• Proper education for nursing, housekeeping, patients, and families

Absolute Contraindications

• Pregnancy (only absolute contraindication) 4
• Breastfeeding women: Must discontinue 4-6 weeks before treatment to minimize mammary irradiation and protect infant 1
• Caution in children/teenagers (use with careful consideration) 4

Common Pitfalls to Avoid

1. Hypothyroidism is an objective, not a complication of hyperthyroidism treatment 4 - expect and plan for it
2. Do not repeat failed hyperthyroidism treatment before 6 months 4
3. Do not perform routine post-treatment scans in thyroid cancer; if required, use only 5 mCi dose 4
4. In cardiovascular risk patients, achieve euthyroid status with propylthiouracil before I-131 4
5. Nodular thyroid with heart disease: Avoid potassium iodide blocking agents 8

Long-Term Safety

The preponderance of evidence supports safety regarding carcinogenesis, though a 2019 re-analysis of long-term data suggested possible increased cancer mortality risk that remains controversial and debated in the literature 9. Over 60 years of use demonstrates proven efficacy and safety in clinical practice 1, 10.